Page 3,605«..1020..3,6043,6053,6063,607..3,6103,620..»

Researchers Don't See Long-Term Benefits From Drug for Preemies

Posted: Published on September 18th, 2014

TUESDAY, Sept. 16, 2014 (HealthDay News) -- Although magnesium sulfate is routinely given to pregnant women at risk for very preterm delivery, new research suggests it won't provide any long-term benefits for infants. After analyzing the effects of magnesium sulfate given to pregnant women, researchers in Australia found it had no benefit on brain, behavioral, growth or functional outcomes among those children when they were assessed at between 6 and 11 years old. The new findings don't negate the fact that the drug is helpful in preventing cerebral palsy in infants, the researchers pointed out in the study, published in the Sept. 17 issue of the Journal of the American Medical Association. Infants born before the 28th week of pregnancy are at greater risk for long-term neurological problems than full-term babies, according to a journal news release. Magnesium sulfate is used to protect the brains of preterm infants. It's also given to pregnant women at high risk for premature delivery to reduce their child's risk of cerebral palsy. In conducting the study, Dr. Lex Doyle of the University of Melbourne, and colleagues, randomly assigned pregnant women to receive magnesium sulfate or a placebo. A total of 535 women were given … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Researchers Don't See Long-Term Benefits From Drug for Preemies

Brain imaging research pinpoints neurobiological basis for key symptoms associated with post-traumatic stress disorder …

Posted: Published on September 18th, 2014

PUBLIC RELEASE DATE: 17-Sep-2014 Contact: Lorinda Klein lorindaann.klein@nyumc.org 212-404-3533 NYU Langone Medical Center / New York University School of Medicine @NYULMC NEW YORK, NY, September 17, 2014 - In a novel brain-imaging study among trauma victims, researchers at NYU Langone Medical Center have linked an opioid receptor in the brain -- associated with emotions -- to a narrow cluster of trauma symptoms, including sadness, emotional detachment and listlessness. The study, published online today in the journal JAMA Psychiatry, holds important implications for targeted, personalized treatment of post-traumatic stress disorder, or PTSD, a psychiatric condition affecting more than 8 million Americans that can cause a wide range of debilitating psychiatric symptoms. "Our study points toward a more personalized treatment approach for people with a specific symptom profile that's been linked to a particular neurobiological abnormality," says lead author Alexander Neumeister, MD, director of the molecular imaging program in the Departments of Psychiatry and Radiology at NYU School of Medicine, and Co-Director of NYU Langone's Steven and Alexandra Cohen Veterans Center for the Study of Post-Traumatic Stress Disorder and Traumatic Brain Injury. "Understanding more about where and how symptoms of PTSD manifest in the brain is a critical part of research efforts … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Brain imaging research pinpoints neurobiological basis for key symptoms associated with post-traumatic stress disorder …

Troy Eccleston hopes Russian treatment will transform his MS

Posted: Published on September 18th, 2014

Sept. 17, 2014, 5:09 p.m. ALBION Park Rails Troy Eccleston and his partner Ainslie Sackey have reached their ambitious fundraising target of $70,000 that will allow Troy to travel to Russia for month-long treatment in Russia. Ainslie Sackey and Troy Eccleston with the patchwork quilt they were presented with by their supporters at Albion Park Community Centre. ALBION Park Rails Troy Eccleston and his partner Ainslie Sackey have reached their ambitious fundraising target of $70,000 that will allow Troy to travel to Russia for month-long treatment in Russia. The Haematopoietic Stem Cell Transplantation treatment (HSCT) will hopefully transform Troys Multiple (MS) which has slowly eroded his quality of life over the past few years. Troy will receive his treatment from Dr Dennis Federenko at Pirigovs National Surgical Medical Centre in Moscow and will be one of eight Australians getting treatment at the centre. I just want to be able to get out of the wheelchair again and even if I can back to using a walking stick it will make a massive difference at the moment I either sit here on the lounge or rely on Ainslie to get me into the wheelchair, Eccleston said. We are just so appreciative … Continue reading →

Posted in MS Treatment | Comments Off on Troy Eccleston hopes Russian treatment will transform his MS

Global initiative targets progressive multiple sclerosis

Posted: Published on September 18th, 2014

Zephyr/SPL New drugs for multiple sclerosis are of no use in treating the disease's progressive form. When Carol Steinberg was diagnosed with multiple sclerosis (MS) in 1995, there was only one drug approved by the US Food and Drug Administration to treat the disease. Now there are eleven. Yet none of these agents can help Steinberg. She suffers from progressive MS, a form of the disease that is characterized by steadily worsening neurological function. All eleven approved drugs combat the unpredictable symptom outbreaks that are associated with the relapsingremitting form of MS. Around 85% of newly diagnosed patients have the relapsingremitting form; after 10 to 20 years, most of them develop the progressive type. The lack of good treatment options for progressive MS weighs heavily on Steinberg. She uses a wheelchair, but continues to work as a trial lawyer in Newton, Massachusetts. Im constantly afraid of my disease getting worse, she says. A global initiative called the Progressive MS Alliance now hopes to kick-start the development of therapies specifically for Steinberg and the million or so people worldwide living with progressive MS. On 11 September, at a joint meeting of the European and Americas Committees for Treatment and Research in … Continue reading →

Posted in MS Treatment | Comments Off on Global initiative targets progressive multiple sclerosis

8 Month HRT Update – Male to Female (MTF) Hormone Replacement Therapy – Video

Posted: Published on September 18th, 2014

8 Month HRT Update - Male to Female (MTF) Hormone Replacement Therapy Instagram: @llerretallure Twitter: @llerretallure Facebook: facebook.com/llerret Tumblr: llerret.tumblr.com. By: L'lerrt Ailith … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on 8 Month HRT Update – Male to Female (MTF) Hormone Replacement Therapy – Video

Testosterone therapy should only be for men with hypogonadism, experts say

Posted: Published on September 18th, 2014

The Endocrine Society testified today at a meeting of the Food and Drug Administration (FDA) discussing the appropriate population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with its use. Though testosterone use has sharply increased among older men in the past decade, the Society told the FDA that testosterone therapy should be limited to men who meet the diagnostic guidelines for hypogonadism. Testosterone is a key male sex hormone involved in maintaining sex drive, sperm production and bone health. Since testosterone levels tend to naturally decline as men age, lower levels of the hormone do not necessarily mean that an individual has hypogonadism, a condition that results from low testosterone. Clinical manifestations of hypogonadism may include decreased libido, erectile dysfunction, breast enlargement and infertility. Testifying before the FDA joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on behalf of the Endocrine Society, Ronald Swerdloff, MD, professor at the David Geffen School of Medicine at UCLA, said testosterone treatment should be limited to men who have clinical manifestations of hypogonadism and consistently low testosterone levels. "The Endocrine Society also recommends that more data be … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Testosterone therapy should only be for men with hypogonadism, experts say

Endocrine Society Tells FDA Testosterone Therapy Should Only Be for Men with Hypogonadism

Posted: Published on September 18th, 2014

Contact Information Available for logged-in reporters only Newswise Washington, DCThe Endocrine Society testified today at a meeting of the Food and Drug Administration (FDA) discussing the appropriate population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with its use. Though testosterone use has sharply increased among older men in the past decade, the Society told the FDA that testosterone therapy should be limited to men who meet the diagnostic guidelines for hypogonadism. Testosterone is a key male sex hormone involved in maintaining sex drive, sperm production and bone health. Since testosterone levels tend to naturally decline as men age, lower levels of the hormone do not necessarily mean that an individual has hypogonadism, a condition that results from low testosterone. Clinical manifestations of hypogonadism may include decreased libido, erectile dysfunction, breast enlargement and infertility. Testifying before the FDA joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on behalf of the Endocrine Society, Ronald Swerdloff, MD, professor at the David Geffen School of Medicine at UCLA, said testosterone treatment should be limited to men who have clinical manifestations of hypogonadism and consistently low testosterone levels. … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Endocrine Society Tells FDA Testosterone Therapy Should Only Be for Men with Hypogonadism

Building the Sanford Stem Cell Clinical Center Inpatient Facility at the Jacobs Medical Center – Video

Posted: Published on September 18th, 2014

Building the Sanford Stem Cell Clinical Center Inpatient Facility at the Jacobs Medical Center Take a tour of the Sanford Stem Cell Clinical Center Inpatient Facility at the Jacobs Medical Center in La Jolla, California. The ultimate goal for the Sanford Stem Cell Clinical Center is... By: Sanford Stem Cell Clinical Center … Continue reading →

Posted in Stem Cell Research | Comments Off on Building the Sanford Stem Cell Clinical Center Inpatient Facility at the Jacobs Medical Center – Video

Hauser and Horizon back Axol with near 1m new cash

Posted: Published on September 18th, 2014

Cambridge UK stem cell technology startup Axol Bioscience has secured 800,000 in new equity funding bringing on board an elite team of heavy-hitters in the life-science investment world. Dr Hermann Hauser, a Cambridge and Silicon Valley entrepreneurial great, and angel funder Dr Darrin Disley CEO of personalised medicines front runner Horizon Discovery are among the industry heavyweights who have piled into the round. The funding will be used to diversify the companys products and expand its marketing capabilities. Axol produces a range of human cells and tissues from induced pluripotent stem (iPS) cells - a type of stem cell derived from easily-obtained blood or skin cells. The iPS cells are used in the testing of new drug compounds as well as in the development of therapies for diseases such as Alzheimers, which affects 24 million people worldwide. Axol launched its iPS cell-derived neural progenitor cells and neurons in 2013 and has already won contracts to provide its cellular platforms to academic pharmaceutical and biotech research bodies, including Harvard, Cambridge and Oxford Universities, Genentech, Janssen and Takeda Pharmaceuticals. The company, already regarded as a global authority on iPS cell-derived research, is felt to hold significant market advantage as its production methods … Continue reading →

Posted in Stem Cell Research | Comments Off on Hauser and Horizon back Axol with near 1m new cash

Large study reveals new genetic variants that raise risk for prostate cancer

Posted: Published on September 18th, 2014

PUBLIC RELEASE DATE: 17-Sep-2014 Contact: Vanessa Wasta wasta@jhmi.edu 410-614-2916 Johns Hopkins Medicine @HopkinsMedicine In an analysis of genetic information among more than 87,000 men, a global team of scientists says it has found 23 new genetic variants common differences in the genetic code -- that increase a man's risk for prostate cancer. The so-called "meta-analysis," believed to be the largest of its kind, has revealed once hidden mutations among men in a broad array of ethnic groups comprising men of European, African, Japanese and Latino ancestry. The meta-analysis combined information from smaller studies, according to William B. Isaacs, Ph.D., a genetic scientist at the Brady Urological Institute at the Johns Hopkins University School of Medicine. "There is a power in numbers that helped us find new variants that were only hinted at in smaller study populations, especially among minority men, and as we found the same variants across several populations, the evidence became stronger that they were definitively linked to prostate cancer," Isaacs said. To help build the number of samples for the current study, described online Sept. 14 in Nature Genetics, Isaacs and Alan Partin, M.D., Ph.D., Brady Urological Institute director, contributed blood and tissue samples and data from … Continue reading →

Comments Off on Large study reveals new genetic variants that raise risk for prostate cancer

Page 3,605«..1020..3,6043,6053,6063,607..3,6103,620..»